Ever­est climbs clos­er to Covid-19 boost­er mar­ket; A French up­start snags funds to find drugs

Ever­est Med­i­cines said its Covid-19 mes­sen­ger RNA part­ner passed a mid-stage test in­ves­ti­gat­ing its vac­cine against Pfiz­er and BioN­Tech’s Comir­naty.

Prov­i­dence Ther­a­peu­tics’ PTX-COVID19-B was non-in­fe­ri­or to the Big Phar­ma’s shot in a Phase II tri­al com­par­ing the vac­cines in 18- to 64-year-olds in Cana­da and South Africa, Ever­est dis­closed Wednes­day. The shot was test­ed as a two-jab in­tra­mus­cu­lar in­jec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER